A 38-year-old man from Bangalore presents with a 3-year history of recurrent episodes of severe vertigo, each lasting 45 minutes to 2 hours, occurring 2–3 times per month. He reports progressive hearing loss in the left ear and constant low-pitched tinnitus. Between episodes, he experiences a sensation of pressure in the left ear. On examination, he has spontaneous horizontal nystagmus during an acute attack. Audiometry shows sensorineural hearing loss at 250 Hz and 500 Hz with normal hearing at higher frequencies. Which of the following is the most appropriate first-line pharmacological management?

Explanation

## Management of Meniere Disease: First-Line Approach ### Diagnosis Confirmation **Key Point:** This patient has established Meniere disease based on: - Episodic vertigo (45 min–2 hrs) - Fluctuating low-frequency sensorineural hearing loss (250–500 Hz) - Tinnitus and aural fullness - Horizontal nystagmus during attack The 3-year history with 2–3 episodes per month indicates chronic disease requiring long-term management. ### Management Hierarchy for Meniere Disease ```mermaid flowchart TD A[Meniere Disease Confirmed]:::outcome --> B[First-Line: Conservative Management]:::action B --> B1["Dietary sodium restriction<br/>≤2g/day"] B --> B2["Diuretics<br/>HCTZ 25mg daily"] B --> B3["Betahistine<br/>16mg TID"] B --> B4["Vestibular rehabilitation"] B --> B5["Acute: Antiemetics +<br/>vestibular suppressants"] A --> C{Response after<br/>3-6 months?}:::decision C -->|Good| D[Continue conservative Rx]:::action C -->|Partial/Poor| E[Second-Line Therapy]:::action E --> E1["Intratympanic gentamicin<br/>or corticosteroids"] C -->|Severe/Refractory| F[Third-Line: Surgical]:::urgent F --> F1["Endolymphatic sac<br/>decompression"] F --> F2["Labyrinthectomy or<br/>vestibular neurectomy"] ``` ### First-Line Pharmacological Management **High-Yield:** The cornerstone of Meniere disease management is the **conservative triad**: | Agent | Mechanism | Dosing | Evidence | |-------|-----------|--------|----------| | **Sodium restriction** | Reduces endolymphatic fluid volume | <2 g/day | Level 1 (foundational) | | **Diuretics (HCTZ)** | Reduces endolymphatic hydrops | 25 mg once daily | Level 1 | | **Betahistine** | Improves microcirculation in inner ear; H1/H3 agonist | 16 mg TID | Level 1 | | **Vestibular rehab** | Promotes central compensation | 2–3 sessions/week | Level 1 | **Clinical Pearl:** Betahistine is a histamine analogue that acts as an H1 agonist and H3 antagonist. It increases blood flow to the labyrinth and may promote endolymph reabsorption. Doses of 16 mg three times daily are standard in India and Europe. ### Acute Episode Management - **Antiemetics:** Prochlorperazine 5–10 mg IV/IM or metoclopramide 10 mg IV - **Vestibular suppressants:** Diazepam 5–10 mg IV/IM (short-term only) - **Supportive:** Bed rest, hydration, dark room **Mnemonic:** SHED = **S**odium restriction, **H**ydrochlorothiazide, **E**xtended betahistine, **D**ietary compliance ### Why Conservative Management First? **Key Point:** Conservative therapy succeeds in 60–80% of patients with Meniere disease. It is: 1. Non-invasive 2. Reversible 3. Well-tolerated 4. Cost-effective 5. Allows time for natural disease remission (which occurs in ~30% of patients over 5–10 years) ### When to Escalate Second-line therapy (intratympanic gentamicin or corticosteroids) is considered only if: - Inadequate response after 3–6 months of conservative therapy - Frequent, disabling attacks (>4 per month) - Patient preference or need for faster control Surgical intervention is reserved for refractory cases after failed medical and intratympanic therapy.